| Outcome Measures: |
Primary: Change in activation of Brown Adipose Tissue (BAT) (oxidative metabolism and blood flow), Measured with 11C-acetate using dynamic PET/CT acquisition., 30 minutes before and 210 minutes after drug administration|BAT glucose uptake, Assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning, 240 minutes after drug administration | Secondary: Whole-body glucose partitioning, Assessed using i.v. injection of 18FDG with static PET/CT scanning, 300 minutes after drug administration|Whole-body lipolysis, Systemic appearance rate of glycerol and fatty acid determined by perfusion of \[1,1,2,3,3-2H\]-glycerol, \[U-13C\]-palmitate tracers. and concentration of total NEFA, triglycerides, palmitate, oleate, linoleate, glycerol., 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).|Hepatic Glucose production, Systemic appearance rate of glucose determined by perfusion of \[6,6 D2\]-glucose, 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).|Substrate utilisation, VO2 and VCO2 will be measured by indirect calorimetry to calculate carbohydrate and fatty acid oxidation rates., 150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state).|BAT lipolysis, Estimated by quantifying changes in tissue radiodensity with CT., baseline and 300 minutes after drug administration|Changes in pancreatic and gut hormones, measured with ELISA and Milliplex., 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).
|
